Cheryl Morgan-Ihrig, MD
Hematology & Oncology · Dubuque, IANPI 1235108036
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,010 and has fallen 88.1% since, to $120 in 2025.
Across 76 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$173
- E.r. Squibb & Sons, L.L.C.$122
- Novartis$108
- Johnson & Johnson$106
- AbbVie$94
- Amgen$93
- plus $593 from 20 others
What the payments were for
- Food & beverage$1,26498%
- Education$252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 12 | $173 |
| E.r. Squibb & Sons, L.L.C. | 9 | $122 |
| Novartis | 6 | $108 |
| Johnson & Johnson(2 entities) | 5 | $106 |
| AbbVie | 5 | $94 |
| Amgen | 6 | $93 |
| Genentech USA, Inc. | 4 | $72 |
| Tersera Therapeutics LLC | 3 | $59 |
| Pfizer | 3 | $59 |
| Lilly USA, LLC | 3 | $54 |
| Bristol Myers Squibb | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Tesaro, Inc. | 1 | $38 |
| Exelixis Inc. | 2 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Sirtex Medical Inc | 1 | $17 |
| EMD Serono, Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Sysmex Inostics Inc | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $12 |
| Incyte Corporation | 1 | $12 |
How this compares
$1,290 in reported general payments places this provider in the 60th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 32 | $570,827 |
| Lenalidomide | 22 | $364,668 |
| AlecensaAlectinib Hcl | 19 | $348,068 |
| ImbruvicaIbrutinib | 26 | $342,137 |
| PomalystPomalidomide | 12 | $285,221 |
| Abiraterone Acetate | 72 | $213,061 |
| NubeqaDarolutamide | 11 | $155,555 |
| BrukinsaZanubrutinib | 11 | $87,021 |
| EliquisApixaban | 56 | $37,118 |
| VenclextaVenetoclax | 13 | $22,940 |
| XareltoRivaroxaban | 21 | $10,835 |
| Anastrozole | 352 | $4,832 |
| Potassium Chloride | 69 | $1,180 |
| Fluconazole | 37 | $1,157 |
| Acyclovir | 99 | $1,138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $12 | $570,82732 claims |
| Genentech USA, Inc.Alecensa | $72 | $348,06819 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $24 | $342,13726 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $122 | $285,22112 claims |
| PfizerEliquis | $59 | $37,11856 claims |
| AbbVieVenclexta | $94 | $22,94013 claims |
| Johnson & JohnsonXarelto | $106 | $10,83521 claims |
| Lilly USA, LLCOlanzapine | $54 | $28946 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Dubuque
- Mark HermannDubuque$3K
- Eric EngelmanDubuque$536
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
- Donald WenderSioux City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.